Hans Lee, MD, is the director of myeloma research at Sarah Cannon Research Institute.
Linvoseltamab Approval Offers New Off-the-Shelf Option for Heavily Pretreated Multiple Myeloma: Hans Lee, MD
The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and de-escalation to monthly maintenance.